Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Tryptophan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.89 |
| ▸ | MAPT | P10636 | 3/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | BLM | P54132 | 2/20 | 0.89 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 2/20 | 0.89 |
| ▸ | MPO | P05164 | 1/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | APAF1 | O14727 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 3/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.61 |
| ▸ | HTR2C | P28335 | 2/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tryptophan SCHEMBL1675340 | 1.00 | KDM4E (0.89) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL424582 | 1.00 | KDM4E (0.89) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL27137714 | 1.00 | KDM4E (0.89) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL7056081 | 1.00 | KDM4E (0.89) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL424583 | 1.00 | KDM4E (0.89) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL6046200 | 0.95 | KMT2A (0.80) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL4287329 | 0.95 | KDM4E (0.80) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL6033338 | 0.95 | KDM4E (0.80) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL7103661 | 0.95 | KDM4E (0.80) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL23141133 | 0.94 | KMT2A (1.00) | KDM4EMAPTKMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10065989-B2 | Molecular sleds and uses thereof | The Broad Institute Inc. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20150210738-A1 | MOLECULAR SLEDS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-30 | — | — | US | disclosed |
| WO-2014012090-A1 | MOLECULAR SLEDS COMPRISING A POSITIVELY-CHARGED AMINO ACID SEQUENCE AND A MOLECULAR CARGO AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| EP-1305338-A2 | MODIFIED PEPTIDES WITH INCREASED POTENCY | THERATECHNOLOGIES INC. (CA) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002010195-A2 | MODIFIED PEPTIDES WITH INCREASED POTENCY | THERATECHNOLOGIES INC. (CA) | 2002-02-07 | — | — | WO | disclosed |
| EP-0538366-A4 | — | — | 1994-04-20 | — | — | EP | disclosed |
| EP-0538366-A1 | RETROVIRAL PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1993002674-A1 | HIV PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-18 | — | — | WO | disclosed |
| WO-1992013552-A1 | ANTI-AGGREGATORY PEPTIDES CONTAINING AN AROMATIC ESTER OR AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 1992-08-20 | — | — | WO | disclosed |
| WO-1992009297-A1 | HIV PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1992007568-A1 | η-TURN PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-05-14 | — | — | WO | disclosed |
| WO-1992000750-A1 | RETROVIRAL PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-23 | — | — | WO | disclosed |
| WO-1992000948-A1 | INHIBITORS OF RETROVIRAL PROTEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-23 | — | — | WO | disclosed |
| WO-1991007429-A1 | ANTI-AGGREGATORY PEPTIDES CONTAINING A MERCAPTAN OR SULFIDE MOIETY | SMITHKLINE BEECHAM CORPORATION (US) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210738-A1 | MOLECULAR SLEDS AND USES THEREOF | SSB, DDHD2, CD44 | ADORA3 3985/4885KDM4E 3944/4885MAPT 1079/4885 |
| US-10065989-B2 | Molecular sleds and uses thereof | SSB, DDHD2, CD44 | ADORA3 4031/4885KDM4E 4053/4885MAPT 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.